Lilly(US:LLY) 智通财经网·2026-02-09 14:44Core Viewpoint - Eli Lilly (LLY.US) has announced a definitive acquisition agreement with Orna Therapeutics to enhance its position in cell therapy and gene drug sectors, with a potential total payout of up to $2.4 billion to Orna's shareholders [1] Group 1: Acquisition Details - Eli Lilly's acquisition of Orna includes a cash payment to shareholders, which may reach up to $2.4 billion, consisting of upfront payments and milestone payments tied to specific clinical development achievements [1] - The acquisition focuses on Orna's circular RNA technology platform and in vivo CAR-T pipeline, which are expected to strengthen Eli Lilly's capabilities in innovative therapies [1] Group 2: Technology and Innovation - Orna specializes in engineering circular RNA combined with novel lipid nanoparticle (LNP) delivery systems, allowing patients' bodies to generate therapeutic cells that target the root causes of diseases [1] - The technology offers advantages such as prolonged expression of therapeutic proteins, addressing limitations in current RNA and cell therapies [1] Group 3: Key Projects - Orna's core project, ORN-252, is a clinically ready in vivo CAR-T therapy targeting CD19, primarily aimed at treating B cell-mediated autoimmune diseases, which aligns with Eli Lilly's strategic focus [1]